Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer.

TP53 mutations were negative predictive in both variant subgroups ( n = 30; P = 0.001) with a strong trend in variant 1 [2.6 month (95% CI: 0.0–10.9) versus 15.9 months (95% CI: 1.4–30.6); P = 0.068] and reaching statistical significance in variant 3a/b ( P = 0.022).

also in 5,725 other papers

In total, PFS of TP53 co-mutated patients was 3.9 months [ n = 60 (95% CI: 2.4–5.6)] and 10.3 months in TP53 wt patients [ n = 168 (95% CI: 8.6–12.0)] regardless of treatment ( P < 0.001) (Figure 3 A and supplementary Table S2 , available at Annals of Oncology online). The ALK variant 3a/b subgroup (cohorts A–D, n = 20) showed a nonsignificant trend toward better PFS with 11.9 months (95% CI: 0.9–23.1) versus variant 1 ( n = 31) with 7.9 months (95% CI: 1.6–14.4) ( P = 0.285).

also in 5,406 other papers